Evidence map›Paper›PMID 36056292›Full record

ArticleProbiotics and antimicrobial proteins2023

Intestinal Microbiomics and Metabolomics Insights into the Hepatoprotective Effects of Lactobacillus paracasei CCFM1222 Against the Acute Liver Injury in Mice.

Weiling Guo, Shumao Cui, Xin Tang, Qiuxiang Zhang, Jianxin Zhao, Bingyong Mao, Hao Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Probiotics and antimicrobial proteins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Sulforaphane-ProducingFood science & nutrition · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Effects of fasting and inflammatory challenges on the swine hepatic metabolome.Comparative biochemistry and physiology. Part D, Genomics & proteomics · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Frontiers in cellular and infection microbiology · 2025
    Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Weiling GuoState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China.
Shumao CuiState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China.
Xin TangState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China.
Qiuxiang ZhangState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China.
Jianxin ZhaoState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China.
Bingyong MaoState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China. maobingyong@jiangnan.edu.cn.
Hao ZhangState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China.
State Key Laboratory of Food Science and Technology · CNJiangnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, acute liver injury (ALI) has received wide-range attention in the world due to its relatively high morbidity and mortality. This study aimed to explore the hepatoprotective effect of Lactobacillus paracasei CCFM1222 against lipopolysaccharide (LPS)-induced ALI mice and further elaborate its mechanism of action from the perspective of intestinal microbiomics and metabolomics. The results displayed that L. paracasei CCFM1222 pretreatment significantly decreased the serum ALT, and AST levels, inhibited the releases of hepatic TNF-α, IL-1β, and IL-6 levels, and activated the SOD, CAT, and GSH-Px activities in LPS-treated mice. The cecal short-chain fatty acid (SCFAs) levels were increased in LPS-treated mice with L. paracasei CCFM1222 pretreatment. In addition, L. paracasei CCFM1222 pretreatment remarkably shifted the intestinal microbiota composition, including the higher abundance of Faecalibaculum, Bifidobacterium, and lower abundance of the Prevotellaceae NK3B31 group, which is positively associated with the cecal propionic, butyric, valeric, isobutyric, and isovaleric acids. The metabolomics based on UPLC-QTOF/MS revealed that L. paracasei CCFM1222 pretreatment significantly regulated the composition of feces metabolites in LPS-treated mice, especially the potential biomarker-related butanoate metabolism, vitamin B6 metabolism, D-glutamine and D-glutamate metabolism, tryptophan metabolism, caffeine metabolism, arginine biosynthesis, arginine, and proline metabolism. Moreover, L. paracasei CCFM1222 pretreatment remarkably regulated the expression of gene-associated ALI (including Tlr4, Myd88, Nf-kβ, iNOS, Cox2, Iκ-Bα, Nrf2, and Sirt-1). In conclusion, these results suggest the possibility that L. paracasei CCFM1222 supplementation has beneficial effects on preventing the occurrence and development of ALI by inhibiting the inflammatory responses and altering intestinal microbiota composition and their metabolites.

Indexed as

Lacticaseibacillus paracaseiAnimalsAntioxidantsLipopolysaccharidesLiverMetabolomicsMiceAntioxidantsLipopolysaccharidesAcute liver injuryLactobacillus paracaseiMetabolomicsMetagenomicmRNA expression

Identifiers

PMID36056292
OpenAlexW4294310623

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.